CONNECTA Therapeutics — Seed (estimated) · €1.7M

This was CONNECTA's first round, a €1.7M capital increase led by Inveready through Inveready Biotech III. CDTI (via Innvierte), Prous Institute founders Josep and David Prous, and Jordi Fàbrega also invested. It funded CTH120's progress towards a Phase IIa trial in fragile X syndrome. Separately, CONNECTA later received a €247,577 CDTI Neotec grant in 2021, which is not a round.